hVIVO Investor
hVIVO is a contract virology research company that aims to develop antivirals and vaccines in the field of biomedical research.
Technology:
Data-driven Technologies
Industry:
Longevity Industry 2022
Headquarters:
London, England, United Kingdom
Founded Date:
1988
Employees Number:
501-1000
Funding Status:
IPO
Investor Type:
Investor
Number Of Exits:
Series B
Total Funding:
$2.6M
Estimated Revenue:
$10M to $50M
Register and Claim Ownership